We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Apoferritin-Based Nanocapsules Used to Transport Toxic Anticancer Drug

By LabMedica International staff writers
Posted on 08 Nov 2015
A toxic anticancer therapeutic agent was encapsulated in capsules derived from apoferritin, which sequestered the drug until its selective delivery to cancer cells.

Ferritin is a globular protein complex consisting of 24 protein subunits and is the primary intracellular iron-storage protein in both prokaryotes and eukaryotes, keeping iron in a soluble and non-toxic form. More...
Ferritin that is not combined with iron is called apoferritin.

Investigators at Washington State University (Pullman, USA) were looking for a better way to administer the anticancer drug daunorubicin. This drug interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. The drug is administered via rapid intravenous infusion. It cannot be given intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. If administered into the spinal canal, it will cause extensive damage to the nervous system and may lead to death.

To circumvent daunorubicin's toxic properties the investigators loaded a mixture of the hydrophobic drug and hydrophilic poly-L-aspartic acid (PLAA) into molecules of apoferritin under slightly acidic conditions that caused the apoferritin molecules to swell. Back at normal pH, the surface of the drug-carrying apoferritin capsules was modified with hyaluronic acid (HA), which targeted the capsules to the cancer cells' to the HA-receptor CD44.

The drug-bearing capsules were used to treat cultures of human embryonic lung MRC-5 cells and lung cancer A549 cells. Results published in the October 2015 issue of the journal Biomaterials Science revealed that the drug was maintained within the capsules until delivery and subsequent uptake by the cancer cells. Release of the drug by the acidic environment of the cancer cells resulted in death of more than 70% of them with no damage to normal cells.

"Our efficiency in killing the cancer cell was very high with no toxicity to normal cells,'' said senior author Dr. Yuehe Lin, professor of mechanical and materials engineering at Washington State University. "At the cell level, we were able to demonstrate it was very effective.''

Related Links:

Washington State University



Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.